[针对急性骨髓性白血病的基于venetoclax的诱导疗法的有效性和安全性]
Juan Feng1, Rui-Feng Yuan1, Hai-Long Tang1
1Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shannxi Province, China.
Zhongguo shi yan xue ye xue za zhi
|August 8, 2023
概括
基于Venetoclax的化疗在新诊断和复发/耐药急性髓性白血病 (AML) 患者中显示出有希望的疗效和良好的耐受性. 这种治疗提供了显著的反应率和可管理的不良事件,包括血液毒性和感染.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床药理学 临床药理学
背景情况:
- 急性髓性白血病 (AML) 提出了重大挑战,特别是新诊断的 (ND) 患者无法接受密集治疗,以及患有复发/耐药 (R/R) 疾病的患者.
- 基于Venetoclax (VEN) 的诱导化疗是一种新兴的AML治疗策略.
研究的目的:
- 评估基于VEN的诱导化疗的疗效和安全性.
- 评估ND和R/RAML患者的治疗反应,生存结果和不良事件.
主要方法:
- 来自51名AML患者 (32名ND,19名R/R) 的临床数据的回顾性分析,这些患者于2021年2月至2022年4月期间接受治疗.
- 评估完全缓解 (CR) /不完全血液恢复 (CRi) 的CR,客观缓解率 (ORR),最小残留疾病 (MRD) 状态,不良事件 (AE),总生存率 (OS) 和无进展生存率 (PFS).
主要成果:
- 一个疗程后,CR/CRi率为65.6% (ND-AML) 和36.9% (R/R-AML);ORR分别为81.3%和42.1%.
- 中位数的PFS为8个月 (ND-AML) 和3个月 (R/R-AML);中位数的OS为13个月 (ND-AML) 和5个月 (R/R-AML).
- 3级+颗粒细胞减小 (96%),贫血 (90.2%) 和血小板减小 (84.3%) 的高发病率;感染是最常见的非血液学AE (23.5%).
结论:
- 基于VEN的疗法在ND和R/RAML患者中显示出良好的治疗反应和可接受的安全概况.
- 血液毒性和感染是与此疗法相关的主要不良事件.
- 实现CR/CRi显著与改善的整体生存结果相关.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
199
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
199